Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.

ABSTRACT:

Background

Serum phosphorus control is critical for chronic kidney disease (CKD) 5D patients. Currently, clinical profile for an oral phosphorus binder in the mainland Chinese population is not available.

Objective

To establish the efficacy, safety, and tolerability of lanthanum carbonate in CKD 5D patients.

Design

Multicenter, randomized, double blind, placebo-controlled study. A central randomization center used computer generated tables to allocate treatments.

Setting

Twelve tertiary teaching hospitals and medical university affiliated hospitals in mainland China.

Participants

Overall, 258 hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) adult patients were enrolled.

Intervention

After a 0-3-week washout period and a 4-week lant

SUBMITTER: Xu J 

PROVIDER: S-EPMC3570485 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature